{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T18:46:08Z","timestamp":1733337968380,"version":"3.30.1"},"update-to":[{"updated":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"DOI":"10.1371\/journal.pcbi.1010481","type":"new_version","label":"New version"}],"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000121","name":"Division of Mathematical Sciences","doi-asserted-by":"publisher","award":["2052685"],"id":[{"id":"10.13039\/100000121","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000121","name":"Division of Mathematical Sciences","doi-asserted-by":"publisher","award":["2052676"],"id":[{"id":"10.13039\/100000121","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"With the recent approval by the FDA of the first disease-modifying drug for Alzheimer\u2019s Disease (AD), personalized medicine will be increasingly important for appropriate management and counseling of patients with AD and those at risk. The growing availability of clinical biomarker data and data-driven computational modeling techniques provide an opportunity for new approaches to individualized AD therapeutic planning. In this paper, we develop a new mathematical model, based on AD cognitive, cerebrospinal fluid (CSF) and MRI biomarkers, to provide a personalized optimal treatment plan for individuals. This model is parameterized by biomarker data from the AD Neuroimaging Initiative (ADNI) cohort, a large multi-institutional database monitoring the natural history of subjects with AD and mild cognitive impairment (MCI). Optimal control theory is used to incorporate time-varying treatment controls and side-effects into the model, based on recent clinical trial data, to provide a personalized treatment regimen with anti-amyloid-beta therapy. In-silico treatment studies were conducted on the approved treatment, aducanumab, as well as on another promising anti-amyloid-beta therapy under evaluation, donanemab. Clinical trial simulations were conducted over both short-term (78 weeks) and long-term (10 years) periods with low-dose (6 mg\/kg) and high-dose (10 mg\/kg) regimens for aducanumab, and a single-dose regimen (1400 mg) for donanemab. Results confirm those of actual clinical trials showing a large and sustained effect of both aducanumab and donanemab on amyloid beta clearance. The effect on slowing cognitive decline was modest for both treatments, but greater for donanemab. This optimal treatment computational modeling framework can be applied to other single and combination treatments for both prediction and optimization, as well as incorporate new clinical trial data as it becomes available.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1010481","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T17:44:00Z","timestamp":1662140640000},"page":"e1010481","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Optimal anti-amyloid-beta therapy for Alzheimer\u2019s disease via a personalized mathematical model"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-7424","authenticated-orcid":true,"given":"Wenrui","family":"Hao","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6898-5796","authenticated-orcid":true,"given":"Suzanne","family":"Lenhart","sequence":"additional","affiliation":[]},{"given":"Jeffrey R.","family":"Petrella","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"issue":"1","key":"pcbi.1010481.ref001","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mjafi.2020.11.003","article-title":"60 years) presenting with dementia to outpatient department","volume":"78","author":"VK Sashindran","year":"2022","journal-title":"Med J Armed Forces India"},{"issue":"11","key":"pcbi.1010481.ref002","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jamaneurol.2021.3404","article-title":"What the Aducanumab Approval Reveals About Alzheimer Disease Research","volume":"78","author":"JJ Manly","year":"2021","journal-title":"JAMA Neurol"},{"key":"pcbi.1010481.ref003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-3-030-78787-5_50","article-title":"Biomarkers and Precision Medicine in Alzheimer\u2019s Disease","volume":"1339","author":"R Sagar","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"pcbi.1010481.ref004","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/STROKEAHA.121.032614","article-title":"Trials and Treatments for Vascular Brain Health: Risk Factor Modification and Cognitive Outcomes","volume":"53","author":"M Kivipelto","year":"2022","journal-title":"Stroke"},{"issue":"1","key":"pcbi.1010481.ref005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1109\/TBME.2012.2212278","article-title":"Machine learning-based method for personalized and cost-effective detection of Alzheimer\u2019s disease","volume":"60","author":"J Escudero","year":"2013","journal-title":"IEEE Trans Biomed Eng"},{"key":"pcbi.1010481.ref006","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fncom.2019.00054","article-title":"Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer\u2019s Disease","volume":"13","author":"L Stefanovski","year":"2019","journal-title":"Front Comput Neurosci"},{"issue":"1","key":"pcbi.1010481.ref007","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12918-016-0348-2","article-title":"Mathematical model on Alzheimer\u2019s disease","volume":"10","author":"W Hao","year":"2016","journal-title":"BMC Syst Biol"},{"key":"pcbi.1010481.ref008","doi-asserted-by":"crossref","first-page":"6216530","DOI":"10.1155\/2019\/6216530","article-title":"Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer\u2019s Disease","volume":"2019","author":"JR Petrella","year":"2019","journal-title":"Comput Math Methods Med"},{"volume-title":"Optimal control applied to biological models","year":"2007","author":"S Lenhart","key":"pcbi.1010481.ref009","doi-asserted-by":"crossref","DOI":"10.1201\/9781420011418"},{"issue":"1","key":"pcbi.1010481.ref010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.mbs.2007.05.003","article-title":"Optimal Control of a Chronic Myelogenous Leukemia Model","volume":"210","author":"S Nanda","year":"2007","journal-title":"Mathematical Biosciences"},{"issue":"1","key":"pcbi.1010481.ref011","first-page":"1","article-title":"Optimal control with MANF treatment of photoreceptor degeneration","volume":"37","author":"ET Camacho","year":"2020","journal-title":"Mathematical Medicine and Biology"},{"issue":"1","key":"pcbi.1010481.ref012","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3934\/dcdsb.2002.2.473","article-title":"Optimal Control of Treatments in a Two Strain Tuberculosis Model","volume":"2","author":"E Jung","year":"2002","journal-title":"Discrete and Continuous Dynamical Systems"},{"issue":"5","key":"pcbi.1010481.ref013","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2967\/jnumed.117.194720","article-title":"Spatiotemporal Distribution of beta-Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities","volume":"59","author":"A Whittington","year":"2018","journal-title":"J Nucl Med"},{"issue":"1","key":"pcbi.1010481.ref014","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0306-4522(02)00404-9","article-title":"Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures","volume":"115","author":"WH Zheng","year":"2002","journal-title":"Neuroscience"},{"issue":"1","key":"pcbi.1010481.ref015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s40478-018-0650-x","article-title":"Amyloid-beta and phosphorylated tau in post-mortem Alzheimer\u2019s disease retinas","volume":"6","author":"J den Haan","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"pcbi.1010481.ref016","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12264-013-1414-z","article-title":"Tau-induced neurodegeneration: mechanisms and targets","volume":"30","author":"C Beharry","year":"2014","journal-title":"Neurosci Bull"},{"issue":"12","key":"pcbi.1010481.ref017","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.0b013e3181f39adc","article-title":"Neurodegenerative basis of age-related cognitive decline","volume":"75","author":"RS Wilson","year":"2010","journal-title":"Neurology"},{"issue":"12","key":"pcbi.1010481.ref018","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease","volume":"140","author":"A Bejanin","year":"2017","journal-title":"Brain"},{"issue":"2","key":"pcbi.1010481.ref019","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2140\/camcos.2018.13.189","article-title":"An equation-by-equation method for solving the multidimensional moment constrained maximum entropy problem","volume":"13","author":"W Hao","year":"2018","journal-title":"Communications in Applied Mathematics and Computational Science"},{"issue":"3","key":"pcbi.1010481.ref020","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"RA Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"7618","key":"pcbi.1010481.ref021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A plaques in Alzheimer\u2019s disease","volume":"537","author":"J Sevigny","year":"2016","journal-title":"Nature"},{"issue":"4","key":"pcbi.1010481.ref022","first-page":"255","article-title":"Clinical Development of Aducanumab, an Anti-Abeta Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer\u2019s Disease","volume":"4","author":"S Budd Haeberlein","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"volume-title":"Optimal control applied to biological models","year":"1975","author":"WH Fleming","key":"pcbi.1010481.ref023"},{"issue":"1","key":"pcbi.1010481.ref024","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/17513758.2016.1156172","article-title":"The impact of spatial arrangements on epidemic disease dynamics and intervention strategies","volume":"10","author":"MR Kelly","year":"2016","journal-title":"Journal of Biological Dynamics"},{"volume-title":"The Mathematical Theory of Optimal Processes","year":"1962","author":"LS Pontryagin","key":"pcbi.1010481.ref025"},{"issue":"1","key":"pcbi.1010481.ref026","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"S Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"7","key":"pcbi.1010481.ref027","first-page":"667","article-title":"Donanemab in Early Alzheimer\u2019s Disease. Reply","volume":"385","author":"MA Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"pcbi.1010481.ref028","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"S Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"6012","key":"pcbi.1010481.ref029","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease","volume":"330","author":"KG Mawuenyega","year":"2010","journal-title":"Science"}],"updated-by":[{"updated":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"DOI":"10.1371\/journal.pcbi.1010481","type":"new_version","label":"New version"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T18:05:18Z","timestamp":1663265118000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010481"}},"subtitle":[],"editor":[{"given":"Adrianne","family":"Jenner","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1010481","relation":{},"ISSN":["1553-7358"],"issn-type":[{"type":"electronic","value":"1553-7358"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}